Amgen Executive Open To Rx-Price Inflation Caps In Limited Situations

An Amgen executive said he would consider the idea of limiting price increases for brand drugs when companies stop improving their products, but America's Health Insurance Plans CEO Marilyn Tavenner said capping inflation wouldn't be much help in controlling drug prices if companies launch products at high prices, a concern also recently expressed by some congressional Medicare advisers. Joshua Ofman, senior vice president for global value, access and policy at Amgen, was asked about tying annual price increases for branded...